Anaplastic lymphoma kinase (ALK) rearrangements account for 5–6% of all non-small cell lung cancer (NSCLC) cases and are caused by the fusion of ALK with other partner genes. The gene discussed is ALK; the disease is non-small cell lung carcinoma.